MYUNGMOON Pharm Co., Ltd.

DUBLIN--( BUSINESS WIRE )--The "Transdermal Scopolamine: Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering. Global Transdermal Scopolamine Market to Reach $528.5 Million by 2027 In the changed post COVID-19 business landscape, the global market for Transdermal Scopolamine estimated at US$368.7 Million in the year 2020, is projected to reach a revised size of US$528.5 Million by 2027, growing at a CAGR of 5.3% over the analysis period 2020-2027. The U.S. Market is Estimated at $108.7 Million, While China is Forecast to Grow at 4.9% CAGR The Transdermal Scopolamine market in the U.S. is estimated at US$108.7 Million in the year 2020. China, the world's second largest economy, is forecast to reach a projected market size of US$93.2 Million by the year 2027 trailing a CAGR of 4.9% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 5% and 4.2% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 4.4% CAGR. Select Competitors (Total 41 Featured) - Alchem International Alkaloids of Australia ALZA Corporation Baxter International Inc. Caleb Pharmaceuticals Inc Centroflora-Cms Fine Chemicals Corporation GlaxoSmithKline Plc Myungmoon Pharma Co. Ltd. Novartis AG Perrigo Co. Plc Phytex Australia Key Topics Covered: I. METHODOLOGY II. EXECUTIVE SUMMARY 1. MARKET OVERVIEW Influencer Market Insights World Market Trajectories Transdermal Scopolamine - Global Key Competitors Percentage Market Share in 2022 (E) Impact of Covid-19 and a Looming Global Recession Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E) 2. FOCUS ON SELECT PLAYERS 3. MARKET TRENDS & DRIVERS 4. GLOBAL MARKET PERSPECTIVE III. MARKET ANALYSIS IV. COMPETITION Companies Mentioned Alchem International Alkaloids of Australia ALZA Corporation Baxter International Inc. Caleb Pharmaceuticals Inc Centroflora-Cms Fine Chemicals Corporation GlaxoSmithKline Plc Myungmoon Pharma Co. Ltd. Novartis AG Perrigo Co. Plc Phytex Australia For more information about this report visit https://www.researchandmarkets.com/r/mjl3iv

SARASOTA, Fla., Oct. 8, 2021 /PRNewswire/ -- Specialty Pharmacy Nursing Network, Inc (SPNN), a national provider of specialty home infusion nursing services is pleased to announce that Cheryl Allen, BS Pharm, MBA has joined the company as EVP Business Development. Before joining SPNN, Cheryl was EVP Business Development and Industry Relations at Asembia and Principal Consultant with Blue Fin Group. Prior to Blue Fin, Cheryl was VP of Business Development and Industry Relations at Diplomat Pharmacy and held roles at Sanovia and Priority Healthcare. According to Cherylann Gregory, CEO of SPNN, the decision to bring Allen onboard was an easy one, particularly in light of her two decades of experience in specialty pharmacy and developing effective programs to support specialty drug manufacturers and their patients. "We are so excited to have Cheryl join our team. Her ability to create patient-centric solutions on behalf of our stakeholders is just one of the many advantages she brings to the table," Gregory explained. "From our perspective, she's the right person to enhance our current business strategies and lead our company in effectively delivering value to our manufacturer, pharmacy and service partners, and the patients whom we serve on these complex drug therapies." Cheryl Allen added "I am pleased to be joining the SPNN team, the premier nursing services company for patients on drug therapies for rare and orphan diseases, and am looking forward to helping broaden their impact in the specialty market through partnerships with manufacturers, pharmacies, and service providers for these patients." ABOUT SPNN Specialty Pharmacy Nursing Network, Inc. is a nationwide nursing network that focuses on the therapy management of patients with rare, chronic disorders. Our professional staff consists of CRNI®, OCN®, IgCN®, PICC and IV-certified nurses who administer specialty pharmacy therapies to patients in the comfort of their home, physician offices, and ambulatory infusion centers (AIC). For more information on SPNN, please visit . ABOUT HEALTHEDGE Founded in 2005, HealthEdge Investment Partners, LLC, is an operating-oriented private equity firm that focuses exclusively on the healthcare industry. HealthEdge seeks to achieve superior returns by investing in businesses that benefit from the knowledge, experience, and network of relationships of its partners. HealthEdge's partners have more than 100 years of combined operating experience in healthcare as CEOs and investors. For more information on HealthEdge, please visit .